Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 3/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20439555 | 1.00 | HDAC4 (0.43) | HDAC4HDAC1HDAC6FLT3SRC | |
| SCHEMBL20422528 | 0.88 | FLT3 (0.45) | FLT3CSF1RTRPA1RETJAK3 | |
| SCHEMBL20422524 | 0.88 | FLT3 (0.45) | FLT3CSF1RTRPA1RETJAK3 | |
| SCHEMBL20443962 | 0.87 | FLT3 (0.41) | FLT3CSF1RTRPA1RETJAK3 | |
| SCHEMBL20437215 | 0.85 | ITGB3 (0.53) | PTPN1SCN9ACSF1RTRPA1HDAC8 | |
| SCHEMBL20422138 | 0.83 | FLT3 (0.48) | FLT3CSF1RTRPA1RETJAK3 | |
| SCHEMBL20422137 | 0.83 | FLT3 (0.48) | FLT3CSF1RTRPA1RETJAK3 | |
| SCHEMBL7361331 | 0.76 | BCL2 (0.61) | PTPN1SCN9AHDAC8 | |
| SCHEMBL7372617 | 0.74 | HDAC8 (0.56) | HDAC4HDAC1HDAC6PTPN1SCN9A | |
| SCHEMBL20422146 | 0.74 | KIT (0.43) | FLT3RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954236-B2 | Tyrosine amide derivatives as Rho-Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-03-23 | — | — | US | disclosed |
| EP-3573987-B1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2021-03-10 | — | — | EP | disclosed |
| US-20180215758-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-08-02 | — | — | US | disclosed |
| US-20180215758-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-08-02 | — | — | US | disclosed |
| WO-2018138293-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10954236-B2 | Tyrosine amide derivatives as Rho-Kinase inhibitors | ROCK1, ROCK2, CIT | HDAC4 872/4885HDAC1 463/4885HDAC6 340/4885 |
| US-20180215758-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, CIT | HDAC4 872/4885HDAC1 463/4885HDAC6 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.